LeMaitre Vascular Inc  

(Public, NASDAQ:LMAT)   Watch this stock  
Find more results for LMAT
0.00 (0.00%)
Jan 30 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 7.61 - 8.00
52 week 6.48 - 8.50
Open 7.82
Vol / Avg. 50,493.00/27,967.00
Mkt cap 138.10M
P/E 48.48
Div/yield 0.04/1.77
EPS 0.16
Shares 17.37M
Beta -0.04
Inst. own 42%
Jan 12, 2015
LeMaitre Vascular, Inc. at Sidoti & Company's Emerging Growth Institutional Investor Forum
Dec 10, 2014
LeMaitre Vascular, Inc. at Benchmark Micro Cap Discovery Conference
Nov 24, 2014
LeMaitre Vascular Inc at Brean Capital's Life Sciences Summit Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 5.34% 4.96%
Operating margin 10.58% 7.00%
EBITD margin - 11.33%
Return on average assets 4.57% 4.80%
Return on average equity 5.55% 5.85%
Employees 328 -
CDP Score - -


63 2ND AVE
United States - Map
+1-781-2212266 (Phone)
+1-781-4255049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


LeMaitre Vascular, Inc. (LeMaitre Vascular) is a global provider of medical devices and implants for the treatment of peripheral vascular disease. The Company develops, manufacture, and market vascular devices to addresses the needs of vascular surgeons. The Company's diversified portfolio of peripheral vascular devices consists of brand name products that are used in arteries and veins outside of the heart and are well known to vascular surgeons, including the Expandable LeMaitre Valvulotome, the Pruitt F3 Carotid Shunt, and VascuTape Radiopaque Tape. The Company sells 12 product lines, most of which are used in open vascular surgery and some of which are used in endovascular procedures. The Company sells its products primarily through a direct sales force. In August 2014, the Company acquired Xenotis, the manufacturer and marketer of the Omniflow II biological graft for peripheral bypass and dialysis access

Officers and directors

George W. LeMaitre Chairman of the Board, Chief Executive Officer
Age: 49
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
David B. Roberts President, Director
Age: 50
Bio & Compensation  - Reuters
Joseph P. Pellegrino Jr. Chief Financial Officer
Age: 49
Bio & Compensation  - Reuters
Peter R. Gebauer President - International Operations
Age: 60
Bio & Compensation  - Reuters
Robert V. Linden Senior Vice President - Sales, The Americas
Age: 47
Bio & Compensation  - Reuters
Trent G. Kamke Senior Vice President - Operations
Age: 43
Bio & Compensation  - Reuters
Cornelia W. LeMaitre Vice President - Human Resources, Director
Age: 78
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Lawrence J. Jasinski Independent Director
Age: 56
Bio & Compensation  - Reuters
John J. O'Connor Independent Director
Age: 66
Bio & Compensation  - Reuters
John A. Roush Independent Director
Age: 49
Bio & Compensation  - Reuters